Drugs / HDM1005

Trials 12

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07828197 Sep → Oct 2026 expected obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT07559240 May → Jun 2026 overdue obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT07502001 Apr → Dec 2026 expected obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT06637020 Jun → Dec 2024 morbid obesity Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT06640647 Mar → Aug 2024 obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT07521631 Mar 2026 → Feb 2027 expected obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT07109700 Apr 2025 → Jan 2026 overdue type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06886126 Feb → Sep 2025 overdue obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 34 trials
Phase 3 NCT07794397 Sep 2026 → Sep 2028 expected obstructive sleep apnea syndrome Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07417306 Mar 2026 → Aug 2027 expected type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07394114 Feb 2026 → Aug 2027 expected type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07279194 Oct 2025 → Sep 2026 overdue obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as HDM1005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07559240 ↗
11

NCT07794397 ↗

NCT06637020 ↗

NCT06886126 ↗

NCT07394114 ↗

NCT07279194 ↗

NCT07417306 ↗

NCT07502001 ↗

NCT07828197 ↗

NCT07521631 ↗

NCT06640647 ↗

Show 1 more source

Route Subcutaneous “receive either HDM1005 injection or placebo subcutaneously” NCT06637020 ↗